HIMS rebounds on GLP-1 growth and rising earnings estimates, while DXC slumps amid falling sales and eroding investor ...

The partnership between the Danish pharmaceutical giant and the splashy telehealth firm Hims & Hers was strained from the ...

Wall Street’s main indices finished in the green but with lackluster gains, with the Nasdaq rising 0.27 percent, the S&P 500 ...

We came across a bearish thesis on Hims & Hers on FJ Research’s Substack. As of 3ʳᵈ July, Hims & Hers’s share was trading at ...

Investing.com -- Hims & Hers CEO Andrew Dudum has shared new information about the company’s terminated partnership with Novo Nordisk (NYSE: NVO ), which ended in June 2025, in an interview with The ...

On June 25, 2025, two securities class action lawsuits were filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of ...

On this news, Hims & Hers' stock price fell $22.24 per share, or 34.63%, to close at $41.98 per share on June 23, 2025.

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The ...

BHUBANESWAR: The Higher Education department on Monday directed all the universities and colleges in the state to submit compliance report on internal committee ...

The Odisha Government today issued strict instructions to all public and private universities, as well as government and unaided degree colleges under the Higher Education Department, to constitute ...

SO Britain’s second-least worst prince is on manoeuvres. Prince Andrew’s nephew, Harry, has been quietly negotiating behind ...

Kerendia was originally approved in July 2021 to reduce cardiovascular and kidney complications in patients with chronic ...